|
|
|
BMRN Dividend History & Description — BioMarin Pharmaceutical Inc
BioMarin Pharmaceutical is a global biotechnology company that develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Co.'s commercial products include: Vimizim (elosulfase alpha); Naglazyme (galsulfase); Kuvan (sapropterin dihydrochloride); Palynziq (pegvaliase-pqpz); Brineura (cerliponase alfa); Voxzogo (vosoritide); and Aldurazyme (laronidase). Co.'s clinical development programs include: Valoctocogene roxaparvovec, which is an adeno associated virus (AAV5) vector drug development candidate; BMN 307, which is an AAV5 mediated gene therapy; and BMN 225, which is a small-molecule therapy. When considering the BioMarin Pharmaceutical Inc stock dividend history, we have taken known splits into account, such that the BMRN dividend history is presented on a split-adjusted ("apples to apples") basis. BioMarin Pharmaceutical Inc dividend history is presented both in graphical/chart form, and as a BMRN dividend history data table along the right-hand column.
Name: |
BioMarin Pharmaceutical Inc |
Website: |
www.bmrn.com |
Sector: |
Drugs & Pharmaceuticals |
Number of ETFs Holding BMRN: |
61 (see which ones) |
Total Market Value Held by ETFs: |
$2,009,409,625.3 |
Total Market Capitalization: |
$17,145,000,000 |
% of Market Cap. Held by ETFs: |
11.72% |
|
BMRN Stock Dividend HistoryThe BMRN dividend history graphic shown above is presented after taking into consideration any known stock split occurrences, in order to present the most directly comparable BMRN historical dividend comparison possible. Historical dividends, when charted graphically, can reveal the long-term variability and/or growth within the BMRN dividend history record. Also see the BMRN stock dividend history data table along the right-hand column below.
|
|
|
|
Quotes delayed 20 minutes
|
Buy (3.36 out of 4)
100th percentile
|
PARTNER NEWS:Fri, Apr 19, 8:10 AM, Zacks
Novartis (NVS) to Report Q1 Earnings: What to Expect? Novartis (NVS) key drugs Entresto, Kisqali and Pluvicto are likely to have fueled its top and bottom-line numbers in the first quarter.
Thu, Feb 22, 6:10 AM, Zacks
5 Stocks Likely to Gain on Q4 Earnings Today After Market Close We have narrowed our search to five large-cap stocks that are poised to beat on earnings today after market closes. These are BKNG, AMH, FND, BMRN, PBA.
|
|